Regenxbio Inc <RGNX.OQ> expected to post a loss of $1.10 a share - Earnings Preview
Regenxbio Inc RGNX.OQ RGNX.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Rockville Maryland-based company is expected to report a 26.1% increase in revenue to $28.113 million from $22.3 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Regenxbio Inc is for a loss of $1.10 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Regenxbio Inc is $31.50, about 73.6% above its last closing price of $8.33
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.53 | 0.48 | 0.12 | Missed | -75.1 |
Dec. 31 2025 | -1.24 | -1.15 | -1.01 | Beat | 11.9 |
Sep. 30 2024 | -1.11 | -1.12 | -1.17 | Missed | -4.3 |
Jun. 30 2024 | -1.30 | -1.29 | -1.05 | Beat | 18.7 |
Mar. 31 2024 | -1.29 | -1.26 | -1.33 | Missed | -5.6 |
Dec. 31 2023 | -1.30 | -1.27 | -1.43 | Missed | -12.5 |
Sep. 30 2023 | -1.56 | -1.52 | -1.41 | Beat | 7.1 |
Jun. 30 2023 | -1.43 | -1.38 | -1.66 | Missed | -19.9 |
This summary was machine generated August 5 at 13:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
